ResMed, Inspire Medical Shares Down After Eli Lilly Provides Sleep Apnea Study Update
By Josh Beckerman
Shares of ResMed, a breathing technology company, fell after Eli Lilly said its weight-loss drug tirzepatide reduced the severity of sleep apnea in Phase 3 trials.
RedMed's shares dropped the most in 10 months on Monday, retreating 11% to $182.73 in early afternoon trading. The stock has declined 15% in the last 52 weeks.
Citi downgraded breathing technology company ResMed to neutral from buy on Monday.
Needham said in a research note that Lilly's results were in line with its expectations. "Given the relatively modest near-term headwind we expect through FY27, we view today's weakness as a buying opportunity" for ResMed shares.
Meanwhile, shares of Inspire Medical Systems, which provides technology for sleep apnea, were down 15% to $138.17. Stifel Financial reduced its target price for Inspire to $170 from $210 and maintained its hold rating.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 24, 2024 13:43 ET (17:43 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now